Fennec Pharmaceuticals Income Statement Analysis

Revenue, earnings, and profit margins in millions USD

Scroll to see more
Fennec Pharmaceuticals Inc. income statement - Annual data in millions USD
BreakdownFY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018
Period EndingDec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018
Revenue & Gross Profit
Revenue47.5421.251.540.000.170.000.00
Cost of Revenue3.181.260.090.000.000.000.00
Gross Profit44.3519.991.450.000.170.000.00
Operating Expenses
Research & Development0.310.063.534.985.115.615.01
Selling, General & Administrative41.4832.7120.5112.2412.957.405.40
Operating Expenses41.7933.0524.1917.2218.0613.0710.41
Operating Income2.57-13.06-22.74-17.22-17.89-13.07-10.41
Other Income/Expense
Interest Income1.680.440.200.050.090.320.00
Interest Expense-4.163.390.980.13-0.410.000.00
Other Income/Expense-0.16-0.030.18-0.040.10-0.020.17
Income
Income Before Tax-0.07-16.05-23.70-17.35-18.11-12.78-9.89
Income Tax Expense0.370.000.000.000.000.000.00
Net Income-0.44-16.05-23.70-17.35-18.11-12.78-9.89
Net Income - Continuous Operations-0.44-16.05-23.71-17.350.000.000.00
Net Income - Discontinued Operations0.000.000.000.000.000.000.00
EBITDA3.60-12.36-22.57-17.22-18.10-13.01-10.41
EBIT2.57-12.65-22.72-17.22-17.89-13.07-10.41
Depreciation & Amortization1.030.290.150.020.400.060.00
Earnings Per Share
Basic EPS--1.00-1.00-1.00-1.00-1.00-1.00
Diluted EPS--1.00-1.00-1.00-1.00-1.00-1.00
Basic Shares Outstanding27.2926.5726.2826.0123.7019.9018.94
Diluted Shares Outstanding27.2926.5726.2826.0123.7019.9018.94